Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy

Table 1

Dendritic cell vaccines in gastric cancer immunotherapy.

Reference	Title	Status
NCT00004604	A phase I study of active immunotherapy with carcinoembryonic antigen (CEA) RNA-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen	Completed
NCT00005956	A pilot study of active immunotherapy with HER2/neu intracellular domain protein pulsed, autologous, cultured dendritic cells in patients with no evidence of disease after standard treatment for HER2/neu expressing malignancies	Completed
NCT00027534	A phase I study of active immunotherapy with autologous dendritic cells infected with CEA-6D expressing fowlpox-tricom in patients with advanced or metastatic malignancies expressing CEA	Completed
NCT01522820	A phase I clinical trial of mTOR inhibition with rapamycin for enhancing intranodal dendritic cell vaccine induced antitumor immunity in patients with NY-ESO-1 expressing solid tumors	Ongoing
Kono et al. [36]	Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T cell responses in patients with gastric cancer	Completed
Sadanaga et al. [37]	Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas	Completed